HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print April 9, 2004

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.1103588v1 75/6/1102    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teleshova, N. Articles by Pope, M. Search for Related Content PubMed PubMed Citation Articles by Teleshova, N. Articles by Pope, M.

© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.1103588

Received for publication November 25, 2003.
Revised January 26, 2004.
Accepted for publication February 26, 2004.

Article

Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells

Natalia Teleshova ^*, Jennifer Jones ^*, Jessica Kenney ^*, Jeanette Purcell , Rudolf Bohm , Agegnehu Gettie , and Melissa Pope ^*@

*Center for Biomedical Research, Population Council, New York, New York; Tulane National Primate Research Center, Tulane University, Covington, Louisiana; and Aaron Diamond AIDS Research Center, New York, New York

^@ To whom correspondence should be addressed. E-mail: mpope{at}popcbr.rockefeller.edu.

	Abstract

In vivo administration of soluble Flt3L increases dendritic cell (DC) numbers to favor improved DC targeting of vaccine antigens, augmenting vaccine efficiency. In addition to confirming the effectiveness of human Flt3L in macaques, we strove to determine the optimal regimen to elevate numbers of functional DCs. Circulating DCs were identified within lineage^-human leukocyte antigen-DR⁺ cells, which comprised CD11c^-CD123⁺ plasmacytoid DCs (PDCs) and CD123^- cells including CD11c⁺CD123^- myeloid DCs as well as CD11c^-CD123^- cells. Traditionally, DCs have been monitored 1-2 days after 10- to 14-day treatments with Flt3L (100 µg/kg/day). We demonstrate that although standard treatment increased macaque DC percentages, as little as 5-7 days of treatment was sufficient, if not more effective at mobilizing DCs. Moreover, DC frequency continued to escalate over the ensuing days, peaking at 4 days post-7 days of treatment and ultimately decreasing thereafter. As expected, there was a more pronounced increase in the percentages and actual numbers of CD123^- cells (CD11c⁺ and CD11c^- subsets) compared with PDCs. Flt3L-mobilized DCs exhibited slightly increased CD80/CD86 expression but typically still that of immature DCs and were resilient to freeze-thawing. Overnight culture activated the cells, up-regulating CD80/CD86 expression as well as interleukin-12 release, typically being boosted by CD40L. This was even more apparent for enriched DC cultures. These data verify that peak mobilization of large numbers of functional macaque DCs occurs a few days, not immediately, after short-term Flt3L dosing. This has important implications for improved DC-targeting vaccine strategies to prevent infection with human immunodeficiency virus and other pathogens.

Key Words: monkeys • PDC • MDCs • expansion • CD80 • CD86

This article has been cited by other articles:

				R. K. Reeves and P. N. Fultz Characterization of Plasmacytoid Dendritic Cells in Bone Marrow of Pig-Tailed Macaques Clin. Vaccine Immunol., January 1, 2008; 15(1): 35 - 41. [Abstract] [Full Text] [PDF]

				T. L. Papenfuss, A. P. Kithcart, N. D. Powell, M. A. McClain, I. E. Gienapp, T. M. Shawler, and C. C. Whitacre Disease-modifying capability of murine Flt3-ligand DCs in experimental autoimmune encephalomyelitis J. Leukoc. Biol., December 1, 2007; 82(6): 1510 - 1518. [Abstract] [Full Text] [PDF]

				M. Kwissa, R. R. Amara, H. L. Robinson, B. Moss, S. Alkan, A. Jabbar, F. Villinger, and B. Pulendran Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus J. Exp. Med., October 29, 2007; 204(11): 2733 - 2746. [Abstract] [Full Text] [PDF]

				K. N. Brown, A. Trichel, and S. M. Barratt-Boyes Parallel Loss of Myeloid and Plasmacytoid Dendritic Cells from Blood and Lymphoid Tissue in Simian AIDS J. Immunol., June 1, 2007; 178(11): 6958 - 6967. [Abstract] [Full Text] [PDF]

				N. Teleshova, J. Kenney, G. Van Nest, J. Marshall, J. D. Lifson, I. Sivin, J. Dufour, R. Bohm, A. Gettie, and M. Robbiani Local and Systemic Effects of Intranodally Injected CpG-C Immunostimulatory-Oligodeoxyribonucleotides in Macaques J. Immunol., December 15, 2006; 177(12): 8531 - 8541. [Abstract] [Full Text] [PDF]

				N. Teleshova, J. Kenney, and M. Robbiani Dendritic Cells and HIV Infection: Activating Dendritic Cells to Boost Immunity Adv. Dent. Res., April 1, 2006; 19(1): 36 - 41. [Abstract] [Full Text] [PDF]

				N. Teleshova, J. Kenney, J. Jones, J. Marshall, G. Van Nest, J. Dufour, R. Bohm, J. D. Lifson, A. Gettie, and M. Pope CpG-C Immunostimulatory Oligodeoxyribonucleotide Activation of Plasmacytoid Dendritic Cells in Rhesus Macaques to Augment the Activation of IFN-{gamma}-Secreting Simian Immunodeficiency Virus-Specific T Cells J. Immunol., August 1, 2004; 173(3): 1647 - 1657. [Abstract] [Full Text] [PDF]